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Alzheimer’s disease (AD) has been reported to be linked with diabetes mellitus and insulin resistance. Adiponectin
(ADN), an adipocytokine secreted from adipose tissue, is involved in the regulation of insulin sensitivity, energy
homeostasis, and mitochondrial dysfunction. In this study, we examined the effect of ADN on passive avoidance
memory in animal model of sporadic AD (sAD). On days 1 and 3 after cannulation, rats received intracerebroven-
tricular (icv) injection of streptozotocin (STZ) (3 mg/kg). Thirty minutes before the learning process, animals
received saline or ADN in different doses (6, 60, and 600 μg). The step-through latency (STL) and total time spent in
the dark compartment (TDC) were recorded and analyzed. In STZ-treated rats, STL was signiﬁcantly decreased,
whereas TDC showed a dramatic increase. In ADN-treated rats, STL was signiﬁcantly increased (P< 0.01) in all
treatment doses. The number of entries was decreased in all applied doses; however, TDC was reduced only by the
application of 6 ng of ADN (P< 0.05). It can be concluded that ADN is useful to improve the STZ-induced memory
impairment. This study showed, for the ﬁrst time, that icv administration of ADN could improve the memory
acquisition in animal model of sAD.
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Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with memory
impairment and loss of multiple cognitive skills that affects one in ten people over the age
of 65 years. There are two different types of AD: (a) an early-onset familial AD, which is
associated with mutations in amyloid precursor protein (APP) and presenilin genes; and (b) a
more common late-onset or sporadic AD (sAD) (15). The pathological presentation of AD
involves a selective neuronal cell death associated with two hallmark lesions: the intracellular
neuroﬁbrillary tangles (NFTs) and extracellular Aβ deposits in form of senile plaques (22).
Accumulation of aggregated neurotoxic Aβ occurs in speciﬁc brain regions (such as
hippocampus and cerebral cortex) and triggers an inﬂammatory response which in turn
leads to neuronal cell death and gradual cognitive decline (21).
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The hippocampus expresses high levels of insulin receptors (IRs), and intact insulin
signaling is necessary for learning, memory, and synaptic plasticity (29). AD brains have
lower levels of insulin, IRs, and insulin-like growth factor, which could further implicate
insulin resistance in AD pathology (4). Currently, the use of intracerebroventricular (icv)
streptozotocin (STZ) injections, which suppresses IR protein level, is a well-established
animal model of sAD. Indeed, insulin dysfunction leads to overactivation of glycogen
synthase kinase-3β, which in turn causes tau hyper phosphorylation and NFT formation and
potentiates Aβ aggregation (23).
Epidemiologic studies have shown that overweight and obesity are associated with
cognitive impairment, dementia, and increased risk of AD. Proteins secreted from the adipose
tissue, known as adipokines, have important functions in regulating the metabolism of the
whole body (14).
Adiponectin (ADN), the most abundant adipokine present in plasma and cerebrospinal
ﬂuid, is inversely correlated with obesity and diabetes mellitus type 2 (T2DM) (10). ADN
exerts its biological actions through its known receptors, adipoR-1 and adipoR-2, which are
prevalently expressed in skeletal muscle and liver, respectively; however, both receptors have
also been found in hypothalamus and hippocampal neurons (12). ADN diminishes the
expression of pro-inﬂammatory cytokines and increases the anti-inﬂammatory ones (26).
Many reports indicate that ADN has insulin-sensitizing effects and is decreased in insulin-
resistant patients (10). Clinical studies have shown that ADN level decreases in T2DM, mild
cognitive impairment (MCI), and AD (25). Administration of ADN could attenuate insulin
resistance, possibly by decreasing tissue triglyceride levels (27). Considering insulin resis-
tance as a promoting factor in sAD, the aim of this study was to examine whether the insulin-
sensitizing effects of ADN could reverse the STZ-induced dementia in rats.
Materials and Methods
Animals
Adult male Wistar rats (250–300 g, Pasteur Institute, Iran) were housed four per cage in a
temperature controlled room (22± 2 °C), with a 12–12 h light–dark cycle and ad libitum
access to food and water. All studies were performed in accordance with the ethical
guidelines of the “Ethical Committee of Qom University of Medical Sciences,” which are
based on the “NIH Guide for the Care and Use of Laboratory Animals.”
Experimental procedure
A total of 40 rats were divided into six experimental groups (n= 7), namely, Intact, Sham,
STZ, STZ+ADN (6, 60, and 600 ng), which have been shown to be effective in other
dose–response studies (3). Sham group received icv injection of 10 μl of artiﬁcial cerebro-
spinal ﬂuid (aCSF; containing 147 mM NaCl, 2.9 mM KCl, 1.6 mM MgCl, 1.7 mM CaCl,
and 2.2 mM dextrose), whereas the STZ group received STZ (3 mg/kg, icv) on days 1 and 3
after cannulation.
Treatments
Rats were anesthetized with a mixture of ketamine [80 mg/kg, intraperitoneal (ip)] and
xylazine (20 mg/kg, ip) and unilaterally implanted with cannulae (23 gauge) placed in the
lateral ventricles; anteroposterior: Bregma, mediolateral: ±1.5 mm “lateral to the” midline,
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and dorsoventral: −3 mm according to the atlas of Paxinos (18). Two small screws were
inserted into the skull and cannulae were ﬁxed to them using dental cement. After recovery,
icv injections were performed by an injection needle (30 gauge) connected to a 10-μl
Hamilton microsyringe. Rats were conscious during injection and gently restrained by hand.
The injection procedure took 2 min, and the injection needles (extending 1 mm from the end
of the guide cannulae) were left in place for 1 min. On days 1 and 3 after cannulation, animals
received 10 μl volume of vehicle (aCSF) or STZ (3 mg/kg) dissolved in aCSF (20). The
timeline of different procedures is shown in Fig. 1.
Behavioral assessment
The passive avoidance task was used to examine the memory acquisition and retrieval
based on the negative reinforcement, as described elsewhere (28). Shortly, the step-through
passive avoidance apparatus consisted of a light and a dark chamber (30 cm × 20 cm ×
20 cm each). The ﬂoor of the dark chamber is consisted of 2 mm thin, electriﬁed, stainless
steel rods. On days 1 and 3, rats received STZ (3 mg/kg, icv). On day 6, animals were
allowed to explore each chamber for adaptation. On day 7, saline or ADN was injected
30 min before the learning process. Rats were then placed in the lighted chamber, and a
shock (50 Hz, 0.5 mA, 2 s) was delivered, following entrance to the dark compartment.
After 5 min, the immediate memory was tested and step-through latency (STL) and the
number of entries into the dark compartment were measured. Early and late retention tests
were performed 1 and 7 days after training, and the time spent in the dark compartment
(TDC) was recorded up to 300 s.
Statistical analysis
Results are expressed as mean± SEM of STL, TDC, and number of entries. Data were
analyzed using ordinary one-way analysis of variances (ANOVA). Where appropriate,
ANOVA was followed by Bonferroni post-hoc test to determine the group differences.
P< 0.05 was considered as level of statistical signiﬁcance in all comparisons.
Histological veriﬁcation
Following behavioral testing, animals were deeply anesthetized by CO2 inhalation, decapi-
tated, and the brains were removed and ﬁxed in formalin. For histological examination of
injection site, 100-μm-thick coronal sections were taken, and the injection sites were
examined for each side under light microscopy. Among all experiments, the injection trace
of four rats did not ﬁt to the lateral ventricle, and these data were excluded from further
analysis.
Fig. 1. Timeline of the experimental procedure. One week after cannulation, icv injection of ADN/aCSF was
performed 30 min before training
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Results
Effect of icv injection of STZ on memory acquisition in passive avoidance task
The sham-operated rats, which received aCSF (icv) instead STZ, did not show any signiﬁcant
difference compared with the naive animals in any of the parameters (t-test, data not shown).
As shown in Fig. 2A, the mean STL of rats receiving STZ was 11.3± 7.8 s, which was
signiﬁcantly (P< 0.001) less than the STL of sham-operated rats (265.7± 34.3 s).
Comparison of the number of trials to acquisition showed a signiﬁcant difference between
sham and STZ-treated rats (1.14± 0.1 vs. 2.7± 0.5, P< 0.01). The cutoff time was 300 s
(Fig. 2B).
Acute icv ADN administration prevented the STL reduction in STZ-treated rats
Administration of different doses (6, 60, and 600 ng) of ADN into the cerebral ventricles
30 min prior to training, improved both the acquisition and retrieval of passive avoidance
Fig. 2. Effects of icv-STZ injection and ADN treatment on STL during acquisition phase (A) and on the number of trails
to acquisition (B). Values are expressed as mean± SEM. **P< 0.05, ***P< 0.001, STZ vs. Sham. #P< 0.05,
##P< 0.01, ###P< 0.001, STZ+ADN vs. STZ. (n= 7, ANOVA multiple group comparison, Bonferroni post-hoc test)
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memory (Fig. 2A). Injection of 6 ng of ADN signiﬁcantly increased the STL (STZ: 2.7±
0.5 s vs. STZ+ADN6: 285.3± 14.7 s, P< 0.01). Also, ADN at the dose of 60 and 600 ng
enhanced the STL compared with STZ-treated rats (STZ: 2.7± 0.5 s vs. STZ+ADN60:
227.6 ± 47.2 s, P< 0.05 and STZ: 2.7± 0.5 s vs. STZ+ADN600: 250.4± 41.8 s, P< 0.01).
The number of trials to acquisition showed the same pattern of improvement; STZ-treated rats
entered 2.7± 0.5 times, while 6 ng of ADN treatment decreased the number of entries to
1.14± 0.1 (P< 0.01). Injection of 60 and 600 ng of ADN reduced the trials to 1.4± 0.3
(P< 0.05) and 1.14± 0.1 (P< 0.01), respectively (Fig. 2B).
ADN administration before training improved the early memory retrieval
As shown in Fig. 3A, one day after training STZ-treated animals spent signiﬁcantly longer time
in the dark compartment compared with the sham group (STZ: 204.1± 35.5 s vs. 29.3± 29.3 s,
Fig. 3. Early and late retrieval in passive avoidance task shown as TDC on day 1 (A) and day 7 after acquisition (B).
TDC is indicated in seconds, as mean± SEM. *P< 0.05, **P< 0.01, STZ vs. Sham. #P< 0.05, STZ vs. STZ+ADN.
(n= 7, ANOVA, Bonferroni post-hoc test)
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P< 0.05). The same trend in memory impairment was observed 7 days after training (Sham:
27.1± 18.3 vs. STZ: 244.7± 37.5, P< 0.01), which is shown in Fig. 3B.
One-way ANOVA with Bonferroni post-hoc test revealed that ADN only at the dose of
6 ng could improve early memory retrieval, one day after training (STZ: 204.1± 35.5 s vs.
50.4± 26 s, P< 0.05). Other doses could not exert a signiﬁcant effect on early and late
memory retrieval (Fig. 3A and B). The injection of ADN in intact animals did not cause any
signiﬁcant change in assessed parameters compared with the sham-operated rats.
Discussion
The results of this study indicate that icv administration of ADN before the acquisition
process of learning could improve the memory retrieval in rat model of dementia.
Reduced cellular response to insulin leads to hyperinsulinemia, and excessive insulin
increases cell proliferation and also induces oxidative stress (16). Insulin can improve
memory, and insulin deﬁciency plays a key role in memory impairment and development of
dementia (6). In contrast to adipokines, such as tumor necrosis factor-α (TNFα) and
monocyte chemoattractant protein-1, which cause insulin resistance, ADN expression is
reduced in insulin-resistant rats (11). Pro-inﬂammatory cytokines are also involved in insulin
resistance. Elevated levels of interleukin-1β (IL-1β), IL-10, and TNFα, which are inversely
related to serum ADN, increase the risk of T2DM (13). Several pieces of evidence suggest
that the insulin-sensitizing action of ADN depends on modulation of insulin-signaling
molecules and regulation of glucose and lipid metabolism (2). ADN stimulates lipolysis
and lipid oxidation, and thereby regulates lipid transfer into non-adipose tissues. Ceramide, a
cytotoxic and insulin-desensitizing lipid metabolite, is converted to sphingosine-1-phosphate,
a process triggered by ADN that improves hepatic insulin action (24).
Some adipokines such as leptin and ADN are involved in the development of dementia.
Clinical studies have shown that circulating ADN decreases in MCI and AD (25). This is
consistent with our ﬁndings that exogenous ADN injection could improve the impaired
memory after insulin signaling deﬁciency. Others have reported that chronic donepezil
treatment decreases serum leptin, whereas it increases ADN levels in patients with AD (17).
García-Casares et al. (7) showed that lower levels of ADN correlated with a lower gray matter
volume and reduced cerebral glucose metabolism in temporal regions. The brain of older
patients is more vulnerable to lower glucose levels. It is known that astrocytes transform
glucose into lactate, which contributes to synapse and memory formation (8).
A vast number of leptin and ADN receptors are expressed within the hippocampus,
which is involved in learning and memory. ADN has been shown to reduce the level of
oxidative stress and kainic acid-induced cytotoxicity in cultured hippocampal neurons. These
antioxidative and neuroprotective effects of ADN are mediated by the α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid pathway (19). On the other hand, it has been shown that
some adipokines, such as leptin, enhance N-methyl-D-aspartate receptor function and induce
hippocampal long-term potentiation (9). Some evidence from our laboratory showed that icv
administration of ADN could also potentiate synaptic efﬁcacy (unpublished data), which can
further emphasize the involvement of ADN in learning and memory.
ADN directly strengthens hepatic insulin signaling by upregulating IRS-2 expression
through an interleukin (IL)-6-dependent pathway (1). The adaptor protein APPL1 has been
identiﬁed as a key scaffold protein to mediate some actions of both insulin and ADN
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receptors. Thus, APPL1 has been implicated in the insulin-sensitizing effect of ADN (5). This
signaling cross-talk between ADN and insulin receptor could, in part, explain the memory
improving effect of ADN observed in this study.
Conclusion
The results of this study showed, for the ﬁrst time, a direct link between ADN, as an
insulin-sensitizing adipokine, and memory improvement in an animal model of sAD. Further
studies are needed to elucidate the molecular mechanisms underlying the close relationship
between ADN, memory, and dementia.
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